https://www.prnewswire.com/news-releases/huma-investors-have-opportunity-to-lead-humacyte-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302340038.html
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law...
/PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc....
https://markets.businessinsider.com/news/stocks/humacyte-reports-new-dod-funding-for-procurement-of-bioengineered-blood-vessels-1035803874
Humacyte reports new DoD funding for procurement of bioengineered blood vessels | Markets Insider
Humacyte (HUMA) announced that the recently adopted FY 2026 U.S. Department of Defense Appropriations Act includes dedicated funding to support ...
https://www.benzinga.com/quote/HUMA/earnings
Humacyte Earnings Estimates, EPS & Revenue | NASDAQ:HUMA | Benzinga
Discover Humacyte stock earnings estimates, EPS, and revenue analysis with Benzinga. Stay informed on HUMA's financial performance.
earnings estimatesepsrevenuenasdaqhuma
https://markets.businessinsider.com/news/stocks/humacyte-announces-fourth-quarter-and-year-end-2025-financial-results-and-provides-business-update-1035970918
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update...
- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year - - Purchase commitmen...
https://humacyte.com/
Universally Implantable Regenerative Human Tissues - Humacyte Global, Inc.
universallyimplantableregenerativehumantissues
https://markets.businessinsider.com/news/stocks/humacyte-announces-long-term-safety-efficacy-results-of-symvess-1035665630
Humacyte announces long-term safety, efficacy results of Symvess | Markets Insider
Humacyte (HUMA) announced the publication of new, long-term data assessing the durability of Symvess in extremity arterial trauma patients in th...
long termefficacy resultsannouncessafety
https://www.benzinga.com/quote/HUMA/analyst-ratings
Humacyte Analyst Ratings and Price Targets | NASDAQ:HUMA | Benzinga
Explore Humacyte analyst ratings and price targets (NASDAQ:HUMA) on Benzinga. Stay updated on expert opinions and forecasts for HUMA stock.
analyst ratingsprice targetsnasdaqhumabenzinga
https://markets.businessinsider.com/news/stocks/humacyte-announces-planned-maa-for-symvess-in-israel-1035684363
Humacyte announces planned MAA for Symvess in Israel | Markets Insider
Humacyte (HUMA) plans to file a Marketing Authorization Application with the Israel Ministry of Health for approval of the acellular tissue engi...
in israelannouncesplannedmaamarkets
https://markets.businessinsider.com/news/stocks/humacyte-to-participate-in-upcoming-investor-conferences-1035885835
Humacyte To Participate in Upcoming Investor Conferences | Markets Insider
DURHAM, N.C., March 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing uni...
to participateinvestor conferencesupcomingmarketsinsider
https://markets.businessinsider.com/news/stocks/humacyte-receives-symvess-purchase-commitment-1035947488
Humacyte receives Symvess purchase commitment | Markets Insider
Humacyte (HUMA) has received a minimum purchase commitment of $1.475M of the Symvess acellular tissue engineered vessel to facilitate a clinical...
receivespurchasecommitmentmarketsinsider
https://www.prnewswire.com/news-releases/huma-investors-have-opportunity-to-lead-humacyte-inc-securities-fraud-lawsuit-302335570.html
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit
/PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and...
securities fraudhumainvestorsopportunity